CN111423479A - 用于治疗细菌性感染的化合物和方法 - Google Patents

用于治疗细菌性感染的化合物和方法 Download PDF

Info

Publication number
CN111423479A
CN111423479A CN202010068431.7A CN202010068431A CN111423479A CN 111423479 A CN111423479 A CN 111423479A CN 202010068431 A CN202010068431 A CN 202010068431A CN 111423479 A CN111423479 A CN 111423479A
Authority
CN
China
Prior art keywords
group
heterocycle
aryl
optionally substituted
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010068431.7A
Other languages
English (en)
Chinese (zh)
Inventor
J.W.贾内特卡
韩振浮
S.胡特格伦
J.平克纳
C.库苏马诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of CN111423479A publication Critical patent/CN111423479A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202010068431.7A 2013-05-30 2014-05-30 用于治疗细菌性感染的化合物和方法 Pending CN111423479A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361828954P 2013-05-30 2013-05-30
US61/828954 2013-05-30
CN201480043010.1A CN105682665A (zh) 2013-05-30 2014-05-30 用于治疗细菌性感染的化合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480043010.1A Division CN105682665A (zh) 2013-05-30 2014-05-30 用于治疗细菌性感染的化合物和方法

Publications (1)

Publication Number Publication Date
CN111423479A true CN111423479A (zh) 2020-07-17

Family

ID=51989445

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480043010.1A Pending CN105682665A (zh) 2013-05-30 2014-05-30 用于治疗细菌性感染的化合物和方法
CN202010068431.7A Pending CN111423479A (zh) 2013-05-30 2014-05-30 用于治疗细菌性感染的化合物和方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201480043010.1A Pending CN105682665A (zh) 2013-05-30 2014-05-30 用于治疗细菌性感染的化合物和方法

Country Status (9)

Country Link
US (4) US9957289B2 (enExample)
EP (1) EP3003322B1 (enExample)
JP (2) JP6640716B2 (enExample)
CN (2) CN105682665A (enExample)
AU (1) AU2014273962B2 (enExample)
CA (1) CA2913622A1 (enExample)
ES (1) ES2959183T3 (enExample)
HK (1) HK1225649A1 (enExample)
WO (1) WO2014194270A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109762034A (zh) * 2019-02-23 2019-05-17 福建医科大学 新型对苯二甲醛缩d-氨基葡萄糖席夫碱的制备方法
CN116023273A (zh) * 2023-03-29 2023-04-28 思合基因(北京)生物科技有限公司 一种新型碳糖苷及其制备方法

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801521B (zh) 2007-05-14 2015-06-17 纽约州立大学研究基金会 生物膜中细菌细胞内的生理学分散响应诱导
WO2012109263A1 (en) 2011-02-07 2012-08-16 The Washington University Mannoside compounds and methods of use thereof
EP3003322B1 (en) 2013-05-30 2023-09-13 Washington University Mannose derivatives and their use in the treatment of bacterial infections
EA034776B1 (ru) 2015-05-20 2020-03-19 Эмджен Инк. Триазоловые агонисты рецептора apj
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
PT3319959T (pt) 2015-07-06 2021-12-06 Alkermes Inc Inibidores hetero-halo de histona desacetilase
WO2017021549A1 (en) * 2015-08-05 2017-02-09 Enterome Mannose derivatives useful for treating pathologies associated with adherent e. coli
WO2017156508A1 (en) * 2016-03-11 2017-09-14 Fimbrion Therapeutics, Inc. C-glycoside compounds useful for treating disease
US10738070B2 (en) 2016-03-23 2020-08-11 Fimbrion Therapeutics, Inc. Mannose-derived antagonists of FimH useful for treating disease
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
MA46824A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj
MA46827A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
MX394242B (es) 2017-01-11 2025-03-24 Rodin Therapeutics Inc Inhibidores biciclicos de histona desacetilasa
MX2020001484A (es) 2017-08-07 2020-08-20 Rodin Therapeutics Inc Inhibidores bicíclicos de la histona desacetilasa.
JP2021500921A (ja) 2017-10-16 2021-01-14 アンテローム Ｆｉｍｈ遮断剤の治療効率を評価するための新規ツール
US11149040B2 (en) 2017-11-03 2021-10-19 Amgen Inc. Fused triazole agonists of the APJ receptor
EP3788037A1 (en) 2018-05-01 2021-03-10 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
EP3820856B9 (en) * 2018-07-10 2023-07-12 GlaxoSmithKline Intellectual Property Development Limited C-mannoside compopunds useful for the treatment of urinary tract infections
US12297223B2 (en) 2019-05-07 2025-05-13 Glaxosmithkline Intellectual Property Development Limited Compounds
US12351597B2 (en) 2019-06-19 2025-07-08 Glaxosmithkline Intellectual Property Development Limited Substituted biphenyl or phenylheteroaryl-mannosides as antagonists of FimH
CN115361953A (zh) * 2020-03-02 2022-11-18 N·帕特尔 一种药物组合物和使用舍雷肽酶、甘露糖或其衍生物、以及任选存在的抗感染剂的治疗方法
WO2021197363A1 (zh) * 2020-03-31 2021-10-07 苏州大学 2-炔基甘露糖衍生物及其应用
CN113797212B (zh) * 2020-06-11 2023-12-22 兰州大学 一组含有甘露糖结构的抗菌药物的合成方法及活性研究
US20240059726A1 (en) 2020-12-28 2024-02-22 Georgia Tech Research Corporation Glycosylated histone deacetylase inhibitors and methods of making and using the same
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011073112A2 (en) * 2009-12-14 2011-06-23 University Of Basel Mannose derivatives as antagonists of bacterial adhesion
WO2012109263A1 (en) * 2011-02-07 2012-08-16 The Washington University Mannoside compounds and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122602A (en) 1989-02-13 1992-06-16 Miles Inc. Chromogenic merocyanine enzyme substrates
US6420127B1 (en) 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
CA2176808A1 (en) * 1993-11-18 1995-05-26 Scott Hultgren Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
AU7470300A (en) 1999-08-11 2001-03-05 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
ATE419880T1 (de) 2000-06-09 2009-01-15 Baylor College Medicine Kombination von antimikrobiellen wirkstoffen und bakterieller interferenz zum überziehen medizinischer vorrichtungen
US7265245B2 (en) 2003-10-08 2007-09-04 Innovaprotean, S.L Compounds useful for the treatment of diseases associated with the formation of amyloid fibrils
WO2005089733A2 (en) 2004-03-23 2005-09-29 Vib Vzw Anti-adhesive compounds to prevent and treat bacterial infections
SE528382C2 (sv) 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
FR2876798A1 (fr) 2004-10-14 2006-04-21 Univ Clermont Auvergne Diagnostic et traitement de la maladie de crohn
EP2490530A4 (en) 2009-10-22 2014-01-22 Univ Washington COMPOUNDS AND METHOD FOR THE TREATMENT OF BACTERIAL INFECTIONS
WO2012164074A1 (en) 2011-06-03 2012-12-06 University Of Basel Mannose phosphate derivatives as antagonists of bacterial adhesion
EP3003322B1 (en) 2013-05-30 2023-09-13 Washington University Mannose derivatives and their use in the treatment of bacterial infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011073112A2 (en) * 2009-12-14 2011-06-23 University Of Basel Mannose derivatives as antagonists of bacterial adhesion
WO2012109263A1 (en) * 2011-02-07 2012-08-16 The Washington University Mannoside compounds and methods of use thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109762034A (zh) * 2019-02-23 2019-05-17 福建医科大学 新型对苯二甲醛缩d-氨基葡萄糖席夫碱的制备方法
CN109762034B (zh) * 2019-02-23 2022-04-29 福建医科大学 新型对苯二甲醛缩d-氨基葡萄糖席夫碱的制备方法
CN116023273A (zh) * 2023-03-29 2023-04-28 思合基因(北京)生物科技有限公司 一种新型碳糖苷及其制备方法

Also Published As

Publication number Publication date
US20160145289A1 (en) 2016-05-26
AU2014273962A1 (en) 2015-12-17
CA2913622A1 (en) 2014-12-04
CN105682665A (zh) 2016-06-15
ES2959183T3 (es) 2024-02-21
EP3003322A4 (en) 2017-01-25
HK1225649A1 (zh) 2017-09-15
JP2020073543A (ja) 2020-05-14
US20210122776A1 (en) 2021-04-29
AU2014273962B2 (en) 2019-07-25
US20230033327A1 (en) 2023-02-02
US9957289B2 (en) 2018-05-01
US20180194792A1 (en) 2018-07-12
JP6640716B2 (ja) 2020-02-05
EP3003322A1 (en) 2016-04-13
WO2014194270A1 (en) 2014-12-04
EP3003322B1 (en) 2023-09-13
JP2016520618A (ja) 2016-07-14
HK1223546A1 (en) 2017-08-04

Similar Documents

Publication Publication Date Title
US20230033327A1 (en) Compounds and methods for treating bacterial infections
US10273260B2 (en) Compounds and methods for treating bacterial infections
EP3492483A1 (en) Compounds and methods for treating bacterial infections
KR101826371B1 (ko) 신규 히드록삼산 유도체
CN112074507B (zh) 作为抗菌素的化合物
TW202039478A (zh) 新穎咪唑衍生物
JP6514716B2 (ja) ＬｐｘＣ阻害剤としてのイソオキサゾリンヒドロキサム酸誘導体
WO2015027963A1 (zh) 芳环类衍生物、其药物组合物及其应用
CN105636966A (zh) 抗细菌铁载体-氨基青霉素缀合物
TW202417432A (zh) 抗菌化合物
CN110799513B (zh) 环稠合噻唑并-2-吡啶酮、其制备方法及其治疗和/或预防涉及革兰氏阳性菌的疾病的应用
KR102264248B1 (ko) 테트라히드로피리딘 유도체 및 이의 항박테리아제로서의 용도
HK40034028A (en) Compounds and methods for treating bacterial infections
WO2013004116A1 (zh) C-3取代的-9-脱氧-9a-氮杂-9a-高红霉素a衍生物
HK1223546B (en) Mannose derivatives and their use in the treatment of bacterial infections
HK40043214A (en) Compound acting as antibiotics
RU2575477C2 (ru) Соединения для лечения заболеваний, связанных с clostridium difficile
HK40043214B (zh) 作为抗菌素的化合物
WO2020019289A1 (zh) 新型罗丹明染料及其在抗致病菌中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40034028

Country of ref document: HK